


## IRIS Medical G-Probe




*“Cyclodiode is an effective treatment for refractory glaucoma of all etiologies.”*

Murphy CC, Burnett CAM, Spry PGD, Broadway DC, Diamond JP. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma. *Br J Ophthalmol* 87:1252-1257, 2003.



A side view showing the edge of the G-Probe placed on the surgical limbus. The laser emitting fiber is placed directly over the pars plicata to ensure delivery of the beam through the sclera and into the ciliary body.



The design of the probe tip allows for precise placement around the circumference of the limbus.



A posterior view of laser treatment applied to the ciliary body. Eyes are treated up to 3/4 of the circumference with approximately 18 applications to effectively reduce IOP.

|                        |                                                       |
|------------------------|-------------------------------------------------------|
| <b>Laser System</b>    | OcuLight SL, OcuLight SLx,                            |
| <b>Compatibility:</b>  | IQ 810                                                |
| <b>Treatment Beam:</b> | Infrared diode laser (810 nm)                         |
| <b>Aiming Beam:</b>    | Red diode laser (650 nm)                              |
| <b>Spot Size:</b>      | 550 micron at fiber tip<br>400 micron at ciliary body |
| <b>Fiber Length:</b>   | 6' (1.8 m)                                            |
| <b>Handle Length:</b>  | 2.5" (6.5 cm)                                         |

**The G-Probe is intended for single use only.**



Specifications are subject to change without notice. TruFocus, IQ 810, DioPexy, G-Probe, Tri-Mode, MicroPulse, LongPulse, EasyFit, CW-Pulse, TrueCW, UltraView, and DioVet are trademarks. OcuLight, EndoProbe, SmartKey, IRIS Medical, IRIDEX, and the IRIDEX logo are registered trademarks of IRIDEX Corporation.

Products are covered by one or more of the following patents: 5,085,492; 5,088,803; 5,372,595; 5,511,085; 5,663,979.

- Kosoko O, Gaasterland D, Pollack I, Enger C, The Diode Laser Ciliary Ablation Study Group: Abrams D, Belcher CD, Gaasterland D, Liebmann J, Pollack I, Ritch R, Schuman J, Shields MB, Wise J. Long-term outcome of initial ciliary ablation with contact diode laser transscleral cyclophotocoagulation for severe glaucoma. *Ophthalmology* 1996;103:1294-1302.
- Schlote T, Derse M, Rassmann K, Nicaeus T, Dietz K, Thiel HJ. Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. *J Glaucoma* 2001; 10:294-301.
- Hauber FA, Scherer WJ. Influence of total energy delivery on success rate after contact diode laser transscleral cyclophotocoagulation: a retrospective case review and meta-analysis. *J Glaucoma* 2002;11:329-333.
- Lirio JPM, Martinez JA, Altuna J, League J, Reyes RD. Single-setting treatment protocol for diode-laser transscleral cyclophotocoagulation. *Philipp J Ophthalmol* 2004;29(4):171-174.
- Olsen T, Edelhauser H, Lim J, Geroski D: Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. *Invest Ophthalmol Vis Sci* 1995;36:1893-1903.
- Palmer DJ, Cohen J, Torczynski E, Deutsch TA: Transscleral diode laser cyclophotocoagulation on autopsy eyes with abnormally thinned sclera. *Ophthalmic Surg Lasers* 1997;28:495-500.
- Schlote T, Derse M, Zierhut M: Transscleral diode laser cyclophotocoagulation for the treatment of refractory glaucoma secondary to inflammatory eye diseases. *Br J Ophthalmol* 2000;84:999-1003.
- Mistlberger A, Tschiderer H, Ruckhofer J, Grabner G: Transscleral contact diode laser cyclophotocoagulation for refractory glaucoma. *Spektrum der Augenheilkunde* 1997;11(2):45-48.
- Klein S, Rockwood EJ, Baerveldt G: Diode laser versus contact transscleral Nd:YAG cyclophotocoagulation (CPC) for uncontrolled glaucoma. [ARVO Abstract] *Invest Ophthalmol Vis Sci* 1996 37(3):S261 Abstract nr 1192.
- Campbell K: Cyclophotocoagulation: A comparative study using two different wavelengths, Nd:YAG (1064 nm) and diode (810 nm). Abstract American Society for Laser Medicine and Surgery *Lasers Surg Med* 1996,8(suppl):94. Grant Laser Center, Columbus, OH.
- Zweifach E, Wilensky J, Hillman I, Quinones R, Gemperli A: A prospective randomized trial of diode and Nd:YAG lasers in treating glaucoma. [ARVO Abstract] *Invest Ophthalmol Vis Sci* 1997 38(4):S170 Abstract Nr 844.



**Authorized European Representative** Hans J. Lehmann, Dipl.-Ing  
Wiesenstrasse 14 Seelfingen D-78333 Stockach, Germany Tel: +49 (7771) 62386 Fax: +49 (7771) 919535

IRIDEX Corporation 1212 Terra Bella Avenue, Mountain View, CA 94043-1824 USA  
Phone: 650-962-8100 or 800-388-4747 (U.S. only) Fax: 650-962-0486 Web: [www.irismedical.com](http://www.irismedical.com) Email: [info@irismedical.com](mailto:info@irismedical.com)  
Copyright 2005 IRIDEX. Printed in the U.S.A. SG 06/05 5M.

# G-Probe™



Patented tip design offers consistent treatment and ease of use while patient is in a supine position.

## G-Probe Product Benefits Include:

- Noninvasive fiber-optic laser hand-piece specially designed for the selective photocoagulation of ciliary processes.
- An alternative to cryotherapy with significantly less postoperative pain and inflammation.
- Patented design ensures accurate probe placement and spacing of treatment sites.
- Ideal for treatment in the office.

The IRIS Medical G-Probe is used for transscleral cyclophotocoagulation (TSCPC) of the ciliary processes. TSCPC has been shown to be a safe and highly effective method for lowering intraocular pressure (IOP) in patients with uncontrolled glaucoma.<sup>1-4</sup> The G-Probe is used with IRIDEX infrared laser systems, such as the OcuLight® SL/SLx and IQ 810™, which provide an 810 nm treatment beam. The 810 nm wavelength easily passes through the sclera without altering its permeability or ultrastructure,<sup>5,6</sup> and is highly absorbed by the ciliary body pigment epithelium.

TSCPC offers a simple, accurate, effective and gentle treatment alternative to cyclocryotherapy and Nd:YAG. Compared to cyclocryotherapy, it offers a higher rate of success with less inflammation,<sup>7</sup> fewer complications, shorter surgery time, and the opportunity for retreatments.<sup>8</sup> Compared to Nd:YAG, it has a higher initial and repeat success rate,<sup>9</sup> offers increased patient comfort levels due to decreased inflammation, and provides a more durable IOP reduction.<sup>10,11</sup> TSCPC with the G-Probe is an efficient and repeatable treatment that can easily be performed in your office.

